Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) EPS (Weighted Average and Diluted) (2021 - 2025)

Janux Therapeutics (JANX) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$0.51 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 45.71% to -$0.51 in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.83, a 42.97% decrease, with the full-year FY2025 number at -$1.83, down 42.97% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.51 for Q4 2025 at Janux Therapeutics, down from -$0.39 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.1 in Q2 2024 to a low of -$0.62 in Q2 2021.
  • A 5-year average of -$0.38 and a median of -$0.39 in 2025 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): soared 76.19% in 2024, then tumbled 450.0% in 2025.
  • Janux Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.29 in 2021, then tumbled by 34.48% to -$0.39 in 2022, then surged by 38.46% to -$0.24 in 2023, then tumbled by 45.83% to -$0.35 in 2024, then plummeted by 45.71% to -$0.51 in 2025.
  • Per Business Quant, the three most recent readings for JANX's EPS (Weighted Average and Diluted) are -$0.51 (Q4 2025), -$0.39 (Q3 2025), and -$0.55 (Q2 2025).